Hepato-renal Regulation of Water Conservation in Heart Failure Patients With SGLT-2 Inhibitor Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-11-11

Study Completion Date

2021-11-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the effects of Dapagliflozin (FORXIGA) 10mg (n=20) and placebo (n=20) on the renal concentration mechanism, mobilization of Na+ from tissue stores, and mobilization of muscle glycogen and fat, in patients heart failure NYHA classes I and II,with or w/o T2DM in a 4-week double-blind, placebo-controlled, randomized study with 2 treatment arms.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome

NCT07273838

Heart Failure Acute Kidney Injury

NOT_YET_RECRUITING PHASE2

Dapagliflozin Effect on Cardiovascular Outcomes in Haemodialysis for End Stage Renal Disease

NCT04764097

Cardiovascular Diseases End Stage Renal Disease

WITHDRAWN PHASE2/PHASE3

Effects of Dapagliflozin on Inflammatory Factorslevel and Prognosis in Type 2 Diabetes With Acute Myocardial Infarction

NCT05050500

Myocardial Infarction Diabete Type 2 Glucose Intolerance

COMPLETED PHASE4

Dapagliflozin in Mangement of Pulmonary Hypertension Patients

NCT06612086

Pulmonary Hypertension

NOT_YET_RECRUITING PHASE1

Studies of Empagliflozin and Its Cardiovascular, Renal and Metabolic Effects

NCT03485092

Heart Failure Diabetes Mellitus

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are a new class of oral medications used for T2DM, which lower blood glucose levels by increasing renal sodium (Na+) and glucose excretion. However, their applications seem to go beyond glycemic control. Recent studies have shown that treatment with SGLT-2 inhibitors significantly improves cardiovascular outcome, with unprecedented reductions in cardiovascular mortality and heart failure hospitalizations. The underlying mechanism of this surprising effect is unclear.

Our hypothesis is that increased Na+ and glucose excretion induced by SGLT-2 inhibitors predisposes to water loss, to which the body responds by increasing urea production in an effort to prevent dehydration. Urea is accumulated in the renal medulla, where it provides the alternative osmotic driving force for water reabsorption. However, hepatic urea production is an energy-intense process, for which amino acids from skeletal muscle are the ideal fuel because they provide both the nitrogen and the energy needed for urea generation. Alanine is transported from muscle to the liver, where it serves as a substrate for new pyruvate generation, which can then be used for the urea cycle, glucose production or ketone body generation. In the same time, as increasing amounts of alanine are shuttled to the liver, muscle will deplete its glucose reservoirs and reprioritize fuel utilization in favour of fatty acids.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This study will be a 4-week double blind, placebo-controlled, randomized study with 2 treatment arms.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

The assignment of consented patients will occur in a blinded fashion using a randomization scheme generated by a statistician who is not part of the study team and has no contact with the study subject. Once eligibility criteria are met, study participants will be randomly assigned to receive either Dapagliflozin 10mg or matching, identically appearing placebo. Stratified random sampling (by gender) will be performed in order to minimize selection bias. Access to the randomisation code will be controlled and documented. Relevant parties will be blinded to the treatment group assignment.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental

Dapagliflozin, 10mg, oral dose, once every day

Group Type ACTIVE_COMPARATOR

Dapagliflozin 10 MG [Forxiga]

Intervention Type DRUG

24 Hour Urine Collection, Sodium (23Na) MRI and Magnetic Resonance (MR) spectroscopy scan, Blood collection for metabolomic and osmolyte analysis

Control

Matching placebo for dapagliflozin, oral dose, once every day

Group Type PLACEBO_COMPARATOR

Dapagliflozin 10 MG [Forxiga]

Intervention Type DRUG

24 Hour Urine Collection, Sodium (23Na) MRI and Magnetic Resonance (MR) spectroscopy scan, Blood collection for metabolomic and osmolyte analysis

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dapagliflozin 10 MG [Forxiga]

24 Hour Urine Collection, Sodium (23Na) MRI and Magnetic Resonance (MR) spectroscopy scan, Blood collection for metabolomic and osmolyte analysis

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Diagnosis of heart failure NYHA stage I or II - as shown by their medical records
2. Stable anti-hypertensive treatment (\>4 weeks)
3. Male and female patients older than 21 years
4. Willingness to participate and ability to provide informed consent
5. Willingness to use effective birth control if of childbearing potential. Any kind of contraception method will be allowed for the period of the study

Exclusion Criteria

1. Patients with congestive heart failure NYHA stages I (LVEF \>40%) without type 2 diabetes mellitus.
2. Patients with congestive heart failure NYHA stages III and IV
3. Prior serious hypersensitivity reaction to Dapagliflozin (Forxiga®)
4. Treatment with any SGLT-2 inhibitor or combined SGLT-1 and 2 inhibitors within 1 week prior to Visit 1 or during screening period until Visit 1
5. Pregnant and breast-feeding women
6. Diagnosis of type 1 diabetes mellitus
7. Patients with type 2 diabetes mellitus with HbA1C \> 10.5% from most recent medical records or antidiabetic therapies other than metformin, sulfonylureas or gliptins at screening.
8. Patients with type 2 diabetes mellitus whose antidiabetic treatment (metformin and/or sulfonylureas and/or gliptins) has been changed or unstable within 6 weeks prior to Visit 1
9. . Unstable or rapidly progressing renal disease
10. Chronic cystitis and recurrent urinary tract infections
11. Impaired renal function with eGFR\<45 ml/min/1.73m2 or proteinuria \> 0.5 g/24h
12. Severe hepatic impairment (Child-Pugh class C)
13. Any major cardiovascular event/vascular disease within 3 months prior to enrolment, as assessed by the investigator
14. Severe edema (as judged by the investigator)
15. Active cancer, history of bladder cancer
16. HIV infection
17. Patients who have received an organ or bone marrow transplant
18. Patients who have had major surgery in the past 3 months
19. Patients who have severe comorbid conditions likely to compromise survival or study participation
20. Patients who exhibit noticeable anxiety and/or claustrophobia or who exhibit severe vertigo when they are moved into the MRI scanner

1. implanted devices (surgical clips, heart pacemakers or defibrillators, cochlear implants)
2. iron-based tattoos
3. any other pieces of metal or devices that are not MR-Safe anywhere in the body
22. Unwillingness or other inability to cooperate

Minimum Eligible Age

21 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No